Literature DB >> 12589144

Adoptive immunotherapy against kidney targets in dog-leukocyte antigen-identical mixed hematopoietic canine chimeras.

Christian Junghanss1, Alessandra Takatu, Marie-Terese Little, J Maciej Zaucha, Eustacia Zellmer, Murad Yunusov, George Sale, George E Georges, Rainer Storb.   

Abstract

BACKGROUND: Stable mixed-donor-host-hematopoietic chimerism can serve as a platform for adoptive immunotherapy. Infusions of donor lymphocytes (DLI) sensitized against hematopoietic cells converted mixed hematopoietic into full-donor chimerism in dog-leukocyte antigen (DLA)-identical littermates. Whether sensitization against tissue of solid organs leads to organ-specific immunity that can be transferred by DLI was unknown and was investigated in these experiments using the kidney as target.
METHODS: DLA-identical recipients with established stable mixed-donor-host-hematopoietic chimerism were used. In five pairs, hematopoietic stem-cell transplant (HSCT) donors were sensitized by kidney transplantation from the respective chimeras. In a second group, five HSCT donors received vaccinations that were generated from kidney cells of the respective mixed chimeras. Twenty-eight days after sensitization, DLI were administered to the mixed-hematopoietic chimeras.
RESULTS: All HSCT donors rejected their kidney grafts from their mixed-chimeric recipients within 22 to 45 days. DLI caused no sustained graft-versus-kidney effects in the mixed-chimeric recipients. However, DLI donors sensitized by kidney transplantation converted 4 of 5 mixed chimeras into virtually complete (>95%) donor-type chimeras, compared with 1 of 5 mixed chimeras given DLI by vaccination from sensitized donors.
CONCLUSION: Although DLA-identical kidney grafts from mixed-hematopoietic chimeras were readily rejected by their HSCT donors, subsequent transfusions of sensitized-donor lymphocytes into mixed chimeras converted mixed to all-donor chimerism but failed to induce graft-versus-kidney effects. Vaccination strategies in lieu of kidney grafts failed to convert mixed chimerism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12589144     DOI: 10.1097/01.TP.0000045224.52516.FC

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Mixed chimerism renders residual host dendritic cells incapable of alloimmunization of the marrow donor in the canine model of allogeneic marrow transplantation.

Authors:  Steven L Rosinski; Scott S Graves; Deborah A Higginbotham; Rainer Storb
Journal:  Chimerism       Date:  2015-10-02

2.  Canine haematopoietic chimerism analyses by semiquantitative fluorescence detection of variable number of tandem repeat polymorphism.

Authors:  I Hilgendorf; V Weirich; L Zeng; E Koppitz; R Wegener; C Junghanss
Journal:  Vet Res Commun       Date:  2005-02       Impact factor: 2.459

3.  Tolerance to vascularized composite allografts in canine mixed hematopoietic chimeras.

Authors:  David W Mathes; Billanna Hwang; Scott S Graves; James Edwards; Jeff Chang; Barry E Storer; Tiffany Butts-Miwongtum; George E Sale; Richard A Nash; Rainer Storb
Journal:  Transplantation       Date:  2011-12-27       Impact factor: 4.939

4.  Isolation of canine mesenchymal stem cells from amniotic fluid and differentiation into hepatocyte-like cells.

Authors:  Seon-A Choi; Hoon-Sung Choi; Keun Jung Kim; Dong-Soo Lee; Ji Hey Lee; Jie Yeun Park; Eun Young Kim; Xiaoxia Li; Hyun-Yang Oh; Dong-Seok Lee; Min Kyu Kim
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-12-15       Impact factor: 2.416

5.  Stable trichimerism after marrow grafting from 2 DLA-identical canine donors and nonmyeloablative conditioning.

Authors:  Scott S Graves; William Hogan; Christian S Kuhr; Razvan Diaconescu; Michael A Harkey; George E Georges; George E Sale; Eustacia Zellmer; Szczepan W Baran; Szczepan Baran; Christoph Jochum; Brad Stone; Rainer Storb
Journal:  Blood       Date:  2007-03-16       Impact factor: 22.113

6.  Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy.

Authors:  Colleen M O'Connor; Sabina Sheppard; Cassie A Hartline; Helen Huls; Mark Johnson; Shana L Palla; Sourindra Maiti; Wencai Ma; R Eric Davis; Suzanne Craig; Dean A Lee; Richard Champlin; Heather Wilson; Laurence J N Cooper
Journal:  Sci Rep       Date:  2012-02-13       Impact factor: 4.379

7.  Adoptive immunotherapy against allogeneic kidney grafts in dogs with stable hematopoietic trichimerism.

Authors:  Scott S Graves; William J Hogan; Christian Kuhr; Razvan Diaconescu; Michael Harkey; George E Sale; Brad Stone; George E Georges; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.